Earlier, Qu et al. reported that conditional deletion of Msi2 in mouse myofibroblasts in an Msi2F/FCol1a1-Cre mouse model attenuated hepatocellular carcinoma tumor progression [46], thus strengthening our findings that MSI2 in stromal cells is a promising target for cancer therapy. Here, MSI2 is linked to cancer.